Pfizer makes a $4.9 billion bet on obesity drugs with Metsera buyout deal
1. Metsera to be acquired by Pfizer for $4.9 billion. 2. Deal offers a 42.6% premium to Metsera's recent closing price. 3. Metsera's stock rose 59.2% in premarket trading. 4. Milestones could yield up to an additional $22.50 per share. 5. Pfizer aims to strengthen its position in obesity treatments.